BigVision Medical Secures RMB 30 Million in Funding to Accelerate Innovation and Global Expansion in Ophthalmic AI

Recently, Big Vision successfully completed a 30 million yuan financing round, with investments from Suzhou Xinsu New Industry Investment, Xuzhou High-tech Industrial Development Zone Venture Development Co., Ltd., and KSND Venture Capital Investment Ltd. This investment will inject new vitality and momentum into Big Vision, further promoting the company's development and innovation in the field of ophthalmic healthcare.

Eye health is an important component of national health, involving the entire life cycle of people of all ages. It is also a public health and social issue related to people's well-being. Big Vision Medical is committed to the research, production, and sales of artificial intelligence software and hardware systems for ophthalmology, transforming advanced AI technology into new productive forces and deeply integrating with China’s eye health initiatives. This brings innovation and transformation to clinical ophthalmology diagnosis and treatment practices. The company not only possesses strong technical capabilities and innovative power but also adheres to a user demand-oriented approach, providing scientific and efficient system solutions to users.

In December 2018, Big Vision took the lead in launching the dual-modal ophthalmic imaging AI analysis system MIAS 2000. At the same time, it began the research and development and certification process for the ophthalmic OCT imaging auxiliary diagnosis system MIAS 3000, which successfully made it to the list of candidates for the National Ministry of Industry and Information Technology's Artificial Intelligence Medical Device Innovation Task in August 2022. MIAS 3000 has now completed clinical validation with excellent performance in all technical indicators, and is expected to become the world’s first ophthalmic OCT imaging auxiliary diagnosis system to obtain a Class III medical device registration certificate by June next year.

In August 2020, Big Vision's self-developed industry-first fully automatic artificial intelligence OCT BV1000 was launched., providing an effective product technology solution to alleviate the serious contradiction of insufficient ophthalmic medical resources in China. It has been applied in more than 400 medical institutions, providing AI analysis services for over 150,000 people, and the eye health big data platform has accumulated more than 5.5 million OCT image slices.

With the advantages of precise AI algorithms and fully automated operations, Big Vision's AI OCT has been welcomed by medical institutions at all levels, especially by ophthalmology and optometry clinics in district and county-level, grassroots, and remote area hospitals. At the Eye Hospital of Wenzhou Medical University, the General Hospital of the Eastern Theater Command, as well as numerous county people's hospitals such as those in Longchuan (Guangdong), Jiayu (Hubei), Liuhe (Jilin), and Weiyuan (Gansu), and particularly at hospitals located in border areas like Bachu People's Hospital in Xinjiang and Nyingchi People's Hospital in Tibet, Big Vision’s intelligent ophthalmic equipment is playing a significant role in clinical diagnosis and treatment. As myopia prevention and control gain widespread societal attention and intervention technologies develop, we are pleased to see optometry applications becoming a new growth point for OCT. An increasing number of optometry clinics are now equipped with OCT to monitor myopia progression through choroidal changes and effectively warn of the risks of fundus lesions caused by myopia, promoting the overall improvement of myopia prevention and control in China. For optometry institutions, integrating ophthalmic AI has become an essential choice.

Big Vision, with its relentless independent innovation, has continuously expanded its product lines and now fully covers multiple fields such as fundus, dry eye, and myopia prevention and control, demonstrating strong technical capabilities and market competitiveness.In September 2023, Big Vision's dry eye detector BVD6600 series obtained certification and was launched., using large-size Placido rings, more completely covering the cornea, integrating AI-assisted analysis functions, with a user-friendly interface and process design, bringing a better dry eye examination experience for doctors and patients.Big Vision's Fully Automatic AI Ophthalmic Optical Biometer to Obtain Certification and Launch SoonThis "OCT + biometry dual-in-one" device can provide a more comprehensive and intelligent solution for myopia prevention and control screening.

Since its establishment, Big Vision has set the corporate mission to "detect every pair of problematic eyes as early as possible and provide the best treatment solutions." Staying true to our original aspiration, we deeply understand that only by driving medical innovation through scientific research and promoting the transformation of scientific achievements via clinical practice can technology better serve the public. To this end, Big Vision collaborates extensively with leading ophthalmic medical institutions and research centers in the industry to jointly advance progress in ophthalmic medicine.

In 2023, Big Vision Medical, in collaboration with the National Clinical Research Center for Ocular Diseases and the Medical Imaging Processing and Analysis Laboratory of Soochow University, jointly launched the Ophthalmology Artificial Intelligence Innovation Alliance and the Ophthalmology Artificial Intelligence Innovation Center (Base) plan., jointly build an eye health big data platform, aiming to explore the occurrence and development patterns of ophthalmic diseases through big data and AI technology, providing strong support for the research of ophthalmic diseases. To date, 18 ophthalmic artificial intelligence innovation research centers (bases) have been established across China. Every data transmission on the eye health big data platform generates a beam of bright light, which holds the hope of safeguarding the bright vision of every patient.

In 2024, Big Vision Medical successfully reached a scientific research cooperation on ocular vascular information and health engineering with Academician Gu Ning's team from Nanjing University."To jointly explore the relationship between ocular vascular changes and systemic health, as well as major fundamental scientific issues and pressing clinical problems related to vascular diseases. This provides more precise and effective technical solutions for the treatment and prevention of ophthalmic diseases and systemic chronic conditions." The collaboration with Academician Gu Ning once again highlights Big Vision's leading position and innovation capabilities in the field of ophthalmic AI.

At the same time, Big Vision Medical and Shanghai Eye Disease Prevention and Treatment Center signed a strategic cooperation agreement, opening a new chapter in the field of community-based eye health management.Both parties will rely on their respective technical and resource advantages to jointly develop intelligent eye health screening equipment and technology suitable for grassroots use, and explore its application model in primary healthcare institutions. They will also support grassroots eye health management through resource sharing, technical exchanges, and training. This sincere cooperation will further promote the development of intelligent eye health screening at the grassroots level, providing community residents with higher quality and more efficient ophthalmic medical services.

We believe that by working closely with top technology research teams and engaging in in-depth cooperation, we can continuously enhance the scientific research innovation capabilities and technical service levels of enterprises, promote high-quality development in the ophthalmology industry, and advance public eye health initiatives to achieve new progress.

The success of this financing undoubtedly provides strong support for the future development of Big Vision. The company plans to further increase its investment in R&D, continuously launching more innovative products and solutions to meet the growing demands in the field of ophthalmic healthcare.At the same time, Big Vision Medical is also looking globally, strengthening close cooperation with international partners, seizing the "Belt and Road" opportunities, comprehensively expanding overseas markets, and realizing the company's global development strategy.

In this process, Big Vision will also actively respond to the national call to improve the level of medical equipment and information technology, and participate in the construction of a high-quality and efficient healthcare service system. Big Vision's product layout covers a full range of ophthalmic AI diagnostic devices, including fundus, glaucoma, optometry, and ocular surface.Provide comprehensive support for ophthalmic medical institutions, assist in technology upgrades and equipment updates, and enhance the modernization level of medical facilities.

Song Caijun, General Manager of Suzhou Xinsu New Industry Investment, the investor of Big Vision, stated that Big Vision's performance in combining advanced AI with ophthalmic diagnosis and treatment is impressive. By effectively empowering real medical scenarios with advanced AI technology, it not only improves the efficiency and accuracy of diagnosis and treatment but also brings health benefits to a large number of patients, achieving significant social benefits.

Liu, the General Manager of Xuzhou High-tech Industrial Development Zone Venture Development Co., Ltd., the investor of Big Vision, stated that the Big Vision team is dream-driven and full of passion, facing every challenge with a pragmatic spirit. They possess outstanding professional capabilities and teamwork skills. He believes that, inspired by the corporate mission of "detecting every pair of eyes with problems as early as possible and providing the best treatment solutions," the company will continue to achieve innovative breakthroughs in the future.

Tang Chen, General Manager of KSND Venture Capital Investment Ltd., the investor of Big Vision, highly praised the technical strength of Big Vision. He stated that Big Vision has rich technical accumulation in the field of ophthalmic AI, and its developed products are at the leading level in all aspects. In the future, it will create more value in the field of ophthalmic medical care.

Looking ahead, Big Vision will continue to bring more innovative products and solutions to the ophthalmic medical field with even greater enthusiasm and a more pragmatic attitude, safeguarding patients' eye health and contributing to the development of the ophthalmic medical industry.